peterschreiber.media
- BofA began protection of Biohaven (NYSE:BHVN) with a purchase score, citing its drug growth applications for temper and autoimmune problems.
- The funding financial institution mentioned it favored Biohaven’s “’fast-follower’ strategy of advancing medication that rivals have been growing – permitting it to capitalize on an already de-risked scientific path.”
- BofA added that whereas it noticed Biohaven’s (BHVN) efforts as “expansive,” it believed administration had a “monitor report of prudent capital allocation.”
- The financial institution set its value goal for the inventory at $52.
